

WEST Search History

DATE: Monday, August 04, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
L1	(phosphocholine or phosphoserine or phosphotyrosine or phosphoethanolamine) same prodrug\$	13	L1

END OF SEARCH HISTORY

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 13 of 13 returned.**☐ 1. Document ID: US 6569432 B1

L1: Entry 1 of 13

File: USPT

May 27, 2003

US-PAT-NO: 6569432

DOCUMENT-IDENTIFIER: US 6569432 B1

TITLE: Prostate-specific membrane antigen and uses thereof

DATE-ISSUED: May 27, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Israeli; Ron S.	Staten Island	NY		
Heston; Warren D. W.	New York	NY		
Fair; William R.	New York	NY		
Ouerfelli; Ouathek	New York	NY		
Pinto; John	East Norwalk	CT		

US-CL-CURRENT: 424/185.1; 424/277.1, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 2. Document ID: US 6482850 B2

L1: Entry 2 of 13

File: USPT

Nov 19, 2002

US-PAT-NO: 6482850

DOCUMENT-IDENTIFIER: US 6482850 B2

TITLE: Hydrolysis-promoting hydrophobic taxane derivatives

DATE-ISSUED: November 19, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ali; Shaukat	Monmouth Junction	NJ		
Franklin; J. Craig	Skillman	NJ		
Ahmad; Imran	Cranbury	NJ		
Mayhew; Eric	Monmouth Junction	NJ		
Bhattacharya; Soumendu	Plainsboro	NJ		
Koehane; Gil	Piscataway	NJ		
Janoff; Andrew S.	Yardley	PA		

US-CL-CURRENT: 514/449; 549/510, 549/511

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 3. Document ID: US 6399655 B1

L1: Entry 3 of 13

File: USPT

Jun 4, 2002

US-PAT-NO: 6399655

DOCUMENT-IDENTIFIER: US 6399655 B1

TITLE: Method for the prophylactic treatment of cataracts

DATE-ISSUED: June 4, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Juan, Jr.; Eugene	Phoenix	MD		

US-CL-CURRENT: 514/456; 514/912

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6392063 B1

L1: Entry 4 of 13

File: USPT

May 21, 2002

US-PAT-NO: 6392063

DOCUMENT-IDENTIFIER: US 6392063 B1

TITLE: Hydrolysis-promoting hydrophobic taxane derivatives

DATE-ISSUED: May 21, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ali; Shaukat	Monmouth Junction	NJ		
Franklin; J. Craig	Skillman	NJ		
Ahmad; Imran	Cranbury	NJ		
Mayhew; Eric	Monmouth Junction	NJ		
Bhattacharya; Soumendu	Plainsboro	NJ		
Koehane; Gil	Piscataway	NJ		
Janoff; Andrew S.	Yardley	PA		

US-CL-CURRENT: 549/510; 549/511

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: US 6180355 B1

L1: Entry 5 of 13

File: USPT

Jan 30, 2001

US-PAT-NO: 6180355

DOCUMENT-IDENTIFIER: US 6180355 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Method for diagnosing and treating chronic pelvic pain syndrome

DATE-ISSUED: January 30, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alexander; Richard B.	Ellicott City	MD		
Ponniah; Sathibalan	Ellicott City	MD		

US-CL-CURRENT: 435/7.1; 435/7.8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 6. Document ID: US 6107332 A

L1: Entry 6 of 13

File: USPT

Aug 22, 2000

US-PAT-NO: 6107332

DOCUMENT-IDENTIFIER: US 6107332 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Hydrolysis-promoting hydrophobic taxane derivatives

DATE-ISSUED: August 22, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ali; Shaukat	Monmouth Junction	NJ		
Franklin; J. Craig	Skillman	NJ		
Ahmad; Imran	Cranbury	NJ		
Mayhew; Eric	Monmouth Junction	NJ		
Bhattacharya; Soumendu	Plainsboro	NJ		
Koehane; Gil	Piscataway	NJ		
Janoff; Andrew S.	Yardley	PA		

US-CL-CURRENT: 514/449; 510/510, 510/511

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 7. Document ID: US 6028099 A

L1: Entry 7 of 13

File: USPT

Feb 22, 2000

US-PAT-NO: 6028099

DOCUMENT-IDENTIFIER: US 6028099 A

TITLE: Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Juan, Jr.; Eugene	Phoenix	MD		

US-CL-CURRENT: 514/434; 514/456, 514/912

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

---

☐ 8. Document ID: US 6028066 A

L1: Entry 8 of 13

File: USPT

Feb 22, 2000

US-PAT-NO: 6028066

DOCUMENT-IDENTIFIER: US 6028066 A

TITLE: Prodrugs comprising fluorinated amphiphiles

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 514/180; 514/169, 552/507

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

---

☐ 9. Document ID: US 5980929 A

L1: Entry 9 of 13

File: USPT

Nov 9, 1999

US-PAT-NO: 5980929

DOCUMENT-IDENTIFIER: US 5980929 A

TITLE: Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischemia or ocular inflammation

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Juan, Jr.; Eugene	Phoenix	MD		

US-CL-CURRENT: 424/427; 424/423

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 10. Document ID: US 5919813 A

L1: Entry 10 of 13

File: USPT

Jul 6, 1999

US-PAT-NO: 5919813

DOCUMENT-IDENTIFIER: US 5919813 A

**\*\* See image for Reexamination Certificate \*\***

TITLE: Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy

DATE-ISSUED: July 6, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Juan, Jr.; Eugene	Phoenix	MD		

US-CL-CURRENT: 514/432; 514/451, 514/453, 514/456, 514/866

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 11. Document ID: WO 2087465 A2

L1: Entry 11 of 13

File: EPAB

Nov 7, 2002

PUB-NO: WO002087465A2

DOCUMENT-IDENTIFIER: WO 2087465 A2

TITLE: COMPOSITIONS AND METHODS OF DOUBLE-TARGETING VIRUS INFECTIONS AND CANCER CELLS

PUBN-DATE: November 7, 2002

## INVENTOR-INFORMATION:

NAME	COUNTRY
KUCERA, LOUIS S	US
FLEMING, RONALD A	US
ISHAQ, KHALID S	US
KUCERA, GREGORY L	US
MORRIS-NATSCHKE, SUSAN L	US

INT-CL (IPC): A61 D 0/EUR-CL (EPC): C07F009/10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 12. Document ID: WO 200287465 A2 US 20020082242 A1

L1: Entry 12 of 13

File: DWPI

Nov 7, 2002

DERWENT-ACC-NO: 2002-617761

DERWENT-WEEK: 200274

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New phosphocholine lipid compounds containing therapeutic agent used for treating e.g. cancer, brain disease and cardiovascular disease and inhibiting virus replication in cells

INVENTOR: FLEMING, R A; ISHAQ, K S ; KUCERA, G L ; KUCERA, L S ; MORRIS-NATSCHKE, S L

PRIORITY-DATA: 2001US-0844201 (April 27, 2001), 2000US-0693658 (October 19, 2000)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200287465 A2	November 7, 2002	E	000	A61D000/00
US 20020082242 A1	June 27, 2002		035	A61K031/675

INT-CL (IPC): A61 D 0/00; A61 K 31/66; A61 K 31/675; C07 F 9/10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Clip Img	Image								

☐ 13. Document ID: JP 2002537243 W WO 200048572 A1 AU 200030008 A EP 1161226 A1

L1: Entry 13 of 13

File: DWPI

Nov 5, 2002

DERWENT-ACC-NO: 2000-549228

DERWENT-WEEK: 200304

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Improving solubility of therapeutic agents, e.g. propofol or paclitaxel, by insertion of a linker with at least one prim. alcohol group between a phosphocholine (congener) and the therapeutic agent

INVENTOR: BARKER, P L; MORIMOTO, B H

PRIORITY-DATA: 1999US-120483P (February 18, 1999)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002537243 W	November 5, 2002		028	A61K031/56
WO 200048572 A1	August 24, 2000	E	025	A61K009/127
AU 200030008 A	September 4, 2000		000	A61K009/127
EP 1161226 A1	December 12, 2001	E	000	A61K009/127

INT-CL (IPC): A61 K 9/02; A61 K 9/08; A61 K 9/10; A61 K 9/127; A61 K 9/20; A61 K 9/48; A61 K 31/05; A61 K 31/56; A61 K 31/665; A61 K 31/675; A61 K 31/685; A61 K 45/00; A61 K 47/48; A61 P 23/00; A61 P 25/20; A61 P 43/00; C07 D 259/00; C07 D 487/22; C07 F 9/02; C07 F 9/09

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Clip Img	Image								

Generate Collection

Print

Terms	Documents
(phosphocholine or phosphoserine or phosphotyrosine or phosphoethanolamine) same prodrug\$	13

---

**Display Format:**

[Previous Page](#)

[Next Page](#)



**WEST**

Generate Collection

Print

L1: Entry 8 of 13

File: USPT

Feb 22, 2000

DOCUMENT-IDENTIFIER: US 6028066 A

TITLE: Prodrugs comprising fluorinated amphiphiles

Detailed Description Text (22):

The procedure in Example 2 is repeated substituting compound (IX) or its phosphate salt for the fluorinated amphiphilic moiety. The resulting compound is a fluorinated phosphocholine-dexamethasone prodrug having the formula set forth below. ##STR15##

WEST



Generate Collection

Print

L1: Entry 6 of 13

File: USPT

Aug 22, 2000

DOCUMENT-IDENTIFIER: US 6107332 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Hydrolysis-promoting hydrophobic taxane derivatives

Detailed Description Text (29):

High sensitivity differential scanning calorimetry (DSC) was used to examine the effect of addition of taxol and its acylated derivatives on the thermotropic phase properties of phosphocholine bilayers of saturated 1,2-dimyristoyl-sn-glycero-3-phosphocholines (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholines (DPPC), and 1,2-distearoyl-sn-glycero-3-phosphocholines (DSPC). Likewise, three acylated taxol prodrugs were varied in chain lengths from six, twelve, to sixteen carbons. The DSC data showed that taxol had little or no effect on the perturbation of all three PC bilayers as high as 9.1 mol % (Lipid/Drug, 10:1). In contrast, the addition of prodrugs into short-chain DMPC and DPPC bilayers, for instance, caused a significant perturbation as observed by the disappearance of pretransitions and broadening in the main phase transition temperatures ( $T_{sub.m}$ ) of both PCs. However, the perturbation was much significant with the long acyl chains, suggesting the intercalation of the prodrugs acyl chain into the bilayers. The long-chain DSPC bilayers, on the other hand, showed less significant change in the DSC profile at any mol % of prodrugs but indeed show some degree of association with the bilayers.

**WEST**

Generate Collection

Print

L1: Entry 5 of 13

File: USPT

Jan 30, 2001

DOCUMENT-IDENTIFIER: US 6180355 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Method for diagnosing and treating chronic pelvic pain syndrome

Detailed Description Paragraph Table (6):

the expression of the redox gene. 5,804,588 Sep. 8, Quinoline carboxanides and The subject invention concerns novel compounds of the general formula (I) [See Original 1998 their therapeutic use Patent for Chemical Structure Diagram] that are useful in treating disease states, such as those states associated with proteins that mediate cellular activity. The compounds of the subject invention can be used, for example, to inhibit tumor necrosis factor and/or phosphodiesterase IV. The subject invention also concerns methods for treating disease states using the compounds of the invention. 5,801,195 Sep. 1, Immunotherapeutic aryl Novel aryl amides are inhibitors of tumor necrosis factor alpha and can be used to combat 1998 amides cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)propanamide. 5,798,368 Aug. 25, Tetrasubstituted 2-(2,6- Tetrasubstituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF 1998 dioxopiperidin-3-yl)-1- alpha in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxopipendin-3-yl)-4,5,6,7- oxoisindolines and method tetrafluoroisoindoline. of reducing TNF alpha levels 5,795,975 Aug 18, TNF receptor promoter A DNA molecule containing the endogenous first intron-located p55 TNF-R gene 1998 promoter/enhancer sequence is provided. Also provided is a DNA molecule which contains a gene in operative association with a promoter sequence that includes the endogenous first intron-located p55 TNF-R gene promoter/enhancer sequence. 5,795,967 Aug. 18, Tumor necrosis factor Tumor necrosis factor antagonists are administered in therapeutically effective doses to 1998 antagonists and their use suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis factor. The antagonists are useful in suppressing transplantation immunity and in the treatment of autoimmune diseases. 5,795,859 Aug. 18, Peptide which abrogates The present invention provides peptides which have the ability to abrogate TNF toxicity 1998 TNF and/or LPS toxicity and/or LPS toxicity. The present invention further relates to compositions induding these peptides as the active ingredient and methods of anti-inflammatory treatment involving the administration of this composition. The peptides of the present invention are based primarily on residue 1 to 26 of human TNF. 5,789,550 Aug. 4, TRAF inhibitors The invention concerns novel inhibitors of tumor necrosis factor receptor associated 1998 factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals. 5,780,667 Jul. 14, Compounds, compositions Novel cyclohexane derivatives of Formula (I) [See Original Patent for Chemical Structure 1998 and treatment of allergies Diagram] are described herein. These compounds inhibit the production of Tumor and inflammation therewith Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; they are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV and are therefore useful in the treatment of disease states in need of mediation or inhibition thereof. 5,777,176 Jul. 7, 4,4- The present invention relates to novel dimers of 4,4-(disubstituted)cyclohexan-1-ol dimers 1998 (disubstituted)cyclohexan- and delated compounds, pharmaceutical compositions containing these compounds, and 1-ol dimers and related their use in treating allergic and inflammatory diseases and for inhibiting the production of compounds Tumor Necrosis Factor (TNF). 5,777,160

Jul. '7, 1,4,4-(trisubstituted) This invention relates to certain 1,4,4-(trisubstituted)cyclohex-1-ene dimers and related 1998 cyclohex-1-ene dimers and compounds which are useful in treating allergic and inflammatory diseases and for related compounds inhibiting the production of Tumor Necrosis Factor (TNF). 5,776,954 Jul. 7, Substituted pyridyl pyrroles, The present invention addresses substituted pyridyl pyrroles, as well as compositions 1998 compositions containing containing such compounds and methods of treatment. The compounds in the present such compounds and invention are glucagon antagonists and inhibitors of the biosynthesis and action of TNF methods of use alpha and IL1. The compounds block the action of glucagon at its receptors and thereby decrease the levels of plasma glucose. The instant pyrroles are also inhibitors of TNF alpha and IL1 and may be used as antidiabetic agents as well as other cytokine mediated diseases. Cytokine mediated diseases refers to diseases or conditions in which excessive or unregulated production of one or more cytokines occurs. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are cytokines produced by a variety of cells, which are involved in immunoregulation and other physiological conditions, such as inflammation. 5,776,947 Jul. 7, Use of quinoline-3- The use of a quinoline-3-carboxamide compound comprising structure (I), optionally with 1998 carboxamide compounds substituents for the hydrogen atoms shown (H<1-9>), and a salt of compound (I) where (a) for inhibiting the production represents that there are two conjugated double bonds between the atoms comprised of tumor necrosis factor by the dashed line, (b) X1 and X2 are separately selected form an oxygen atom or an (TNF) and/or for the NH<9> group, said X1 and X2 being bound by a single bond to the ring when attached to treatment of septic shock H<7> or H<8> and by a double bond when not bound to H<7> or H<8>, (c) H<1-9>; are hydrogens with the provision that H<9> is only present when at least one of X1 and X2 is the NH<9> group, (d) H<7> and H<8> are hydrogens that are attached to different atoms selected among X1, X2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for inhibiting the production of tumor necrosis factor TNF in a living body and/or the treatment of septic shock in a living body. 5,776,915 Jul. 7, Phosphocholines of Novel retinoid phosphocholines are disclosed having the general Formula (I): [See 1998 retinoids Original Patent for Chemical Structure Diagram] wherein R represents a retinyl or retinoyl moiety. The optical and geometric isomers of compounds of Formula (I) and the pharmaceutically-acceptable salts thereof, are also disclosed. The subject compounds exhibit anti-tumor, anti-psoriatic and anti-inflammatory activities in addition to their inherent Vitamin A-like activities. The invention embraces the novel compounds, pharmaceutical compositions thereof, and methods of using the same. 5,773,582 Jun. 30, Tumor necrosis factor Muteins of human tumor necrosis factor (hTNF), a process for production thereof, and 1998 muteins DNAs encoding these muteins are found to have a superior antitumor activity and lower acute lethal toxicity compared to the wild-type human tumor necrosis factor. 5,773,467 Jun. 30, Benzoluran Benzoluran carboxides and sulphonamides have therapeutic utility, e.g. in the treatment 1998 sulphonanmides of inflammation and asthma, by virtue of their ability to inhibit phosphodiesterases and tumor necrosis factor. 5,772,997 Jun. 30, Monoclonal antibodies A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or 1998 directed to the HER2 growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor receptor function, is disclosed. A method of treatment tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors. 5,770,694 Jun. 23, Genetically engineered BPI The present invention provides a composition comprising a BPI Protein and an anionic 1998 variant proteins compound which composition exhibits (1) no bactericidal activity and (2) endotoxin neutralizing activity. Also, this invention provides methods for using BPI Proteins. 5,770,624 Jun. 23, Certain alpha-substituted Particularly the invention relates to the compounds of formula I [See Original Patent for 1998 arylsulfonamido Chemical Structure Diagram] (I) wherein Ar represents carbocyclic aryl, heterocyclic aryl acetohydroxamic acids or biaryl; R1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl, halo-lower alkyl; R2 represents hydrogen or lower alkyl; R3 and R4 represent independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R3 and R4 together represent lower allylenedioxy; n represents an integer from 1 to 5; pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof; methods for preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting

TNF-alpha activity and matrix-degrading metalloproteinases in mammals using such compounds. 5,770,402 Jun. 23, DNA encoding macrophage Disclosed are novel nucleic acid and peptide compositions comprising a constitutively- 1998 inflammatory protein-1 expressed CC chemokine. Also disclosed are methods of use for MIP-1 gamma amino gamma acid sequences and the DNA segments which encode them in the stimulation of an immune response, the production of limited pyrexia, the treatment of proliferative cell disorders and T-cell mediated diseases, and the prophylaxis of bacterial sepsis in an animal. 5,770,401 Jun. 23, Methods and compositions Methods and compositions for treating allergic reactions, including cutaneous, ocular, 1998 for treating allergic nasal and Bronchial allergic disease, are disclosed. Interleukin-1 and Tumor Necrosis reactions Factor receptors, and analogues thereof, are employed which bind the respective effector competitively and thereby suppress allergic reactions. 5,770,195 Jun 23, Monoclonal antibodies A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or 1998 directed to the her2 growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors. 5,767,151 Jun. 16, 3,3-(disubstituted) The present invention relates to novel 3,3-(disubstituted)-cyclohexan-1-ylidene acetate 1998 cyclohexan-1-ylidene dimers of Formula (I): [See Original Patent for Chemical Structure Diagram] I and related acetate dimers and related compounds, pharmaceutical compositions containing these compounds and their use in compounds treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF). 5,767,120 Jun. 16, Tricyclic derivatives, Disclosed are compounds of Formula I: [See Original Patent for Chemical Structure 1998 compositions and methods Diagram] (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: R<3> is of use alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl, cycloalkyl, acyloxymethyl, alkoxy, alkoxymethyl, or alkyl substituted with cycloalkyl; R<4> is H, alkyl, alkenyl, alkoxy, or --OH. Also disclosed are pharmaceutical compositions containing compounds of Formula methods for inhibiting tumor necrosis factor- alpha and methods for treating septic shock, inflammation, or allergic

Detailed Description Paragraph Table (7):

disease by administering a compound of Formula I. 5,767,097 Jun. 16, Specific modulation of Ribavirin is administered to a patient in a dosage range which is effective to modulate 1998 Th1/Th2 cytokine tympokine expression in activated T cells. In particular, ribavirin is used to suppress Th2- expression by ribavirin in mediated T cell responses and promote Th1-mediated T cell response. Thus, instead of activated T-lymphocytes administering ribavirin in its well-recognized role as an anti-viral agent, ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, hetminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection. 5,766,917 Jun. 16, Method for identifying and Molecules which influence the shedding of the cell-bound p55 Tumor Necrosis Factor 1998 producing a protease receptor (p55-TNF-R), are provided, together with methods of producing them. capable of cleaving the TNF receptor 5,766,865 Jun. 16, Cell lines capable of A method of genetically engineering a cell line capable of detecting bioactive cytokines or 1998 detecting low levels of growth factors is provided. Cells lines produced by this method and methods of using these cytokines in biological fluids cell lines to detect bioactive cytokines or growth factors in a biological fluid are also provided. 5,763,621 Jun 9, Metalloproteinase inhibitors A compound of formula (I): [See Original Patent for Chemical Structure Diagram] 1998 wherein R4 is an optionally substituted C3-C8 cycloalkenyl group. The compounds are inhibitors of matrix metalloproteinases. 5,763,567 Jun. 9, Biologically active peptides The present invention provides peptides having an amino acid sequence that is the amino 1998 from functional domains of acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional bactericidal/permeability- domain or a subsequence thereof, and variants of the sequence or subsequence thereof, increasing protein and uses having at least one of the BPI biological activities, such as heparin binding, heparin thereof neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a

variety of therapeutic uses. 5,763,423 Jun. 9, Pharmaceutical  
alpha-tocopherolphosphocholine and salts thereof have been discovered to possess 1998  
compositions, novel uses, anti-viral, anti-fungal, anti-inflammatory and  
PAF-antagonist activities. The compound and novel form of salts have also been  
discovered to be capable of forming liposomes. The present invention  
tocopherylphosphocholine thus provides methods of treating viral and fungal  
infections, inflammatory disorders and pathophysiological conditions due to PAF  
activity in a mammal by administering to the mammal alpha -tocopherolphosphocholine  
or a pharmaceutically acceptable salt thereof. The invention also provides  
pharmaceutical compositions comprising alpha - tocopherolphosphocholine or a  
pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.  
Further, the invention provides liposomes which comprise alpha  
-tocopherolphosphocholine or a salt thereof as a structural component of the liposome  
bilayer. 5,756,499 May 26, Substituted imidazole Novel 1,4,5-substituted imidazole  
compounds and compositions for use in therapy as 1998 compounds cytokine inhibitors.  
5,753,691 May 19, Agents for inhibiting the The pharmaceutical use of  
1-cinnamoyl-2-pyrrolidinone derivatives having the activities to 1998 production of  
IL-1 beta and inhibit the production of IL-1 beta and the release of TNF alpha. Those  
derivatives are the release of TNF alpha useful in the treatment or prophylaxis of  
the diseases such as chronic rheumatism and sepsis. 5,753,666 May 19, Quinotones and  
their 1-Alkyl-substituted-quinotone-3-carboxamides have therapeutic utility via  
inhibition of 1998 therapeutic use Phosphodiesterase IV esterase and/or Tumor  
Necrosis Factor activity. 5,753,653 May 19, Metalloproteinase The invention relates  
to compounds of the formula [See Original Patent for Chemical 1998 inhibitors,  
pharmaceutical Structure Diagram] I in which Q is a divalent radical having four ring  
atoms which compositions containing together with C\* and N form a six-membered ring,  
each of these four ring atoms being them and their unsubstituted or substituted by a  
suitable substituent and at least one being a heteroatom pharmaceutical uses selected  
from O, N and S, with the remainder being carbon atoms; and Ar is an aryl or  
heteroaryl group. The invention further relates to pharmaceutically acceptable  
prodrugs and pharmaceutically acceptable salts of these compounds. The invention also  
relates to methods of inhibiting the activity of metalloproteinases, especially MMPs  
or TNF alpha by administering a compound of the formula I or a salt or prodrug  
thereof. The invention further relates to pharmaceutical compositions comprising an  
effective amount of these compounds, salts, and prodrugs. 5,753,628 May 19, Peptide  
inhibitors of TNF Peptides which consist of six to eight, predominately D-amino acids  
and which bind to 1998 containing predominantly tumor necrosis factor-alpha, prevent  
tumor necrosis factor-alpha from binding to its D-amino acids receptors and inhibit  
tumor necrosis factor-alpha activity are disclosed. Methods of inhibiting tumor  
necrosis factor-alpha activity and of treating individuals suffering from tumor  
necrosis factor-alpha-mediated diseases and disorders are disclosed. 5,747,514 May 5,  
Metalloproteinase inhibitors The present invention relates to therapeutically active  
hydroxamic acid and carboxylic 1998 acid derivatives, to processes for their  
preparation, to pharmaceutical compositions containing them, and to the use of such  
compounds in medicine. In particular, the compounds are inhibitors of  
metalloproteinases involved in tissue degradation, and in addition are inhibitors of  
the release of tumor necrosis factor from cells. 5,747,474 May 5, Immunosuppression  
by Methods for inducing immunosuppression in animals which need immunosuppressive  
1998 administration of N<6>, treatment involving administration to animals of a  
therapeutically effective amount of the N<6>-disubstituted cyclic AMP agent HE-33 or  
its nucleoside. cAMP's, analogues thereof, and related nucleosides 5,744,304 Apr. 28,  
Inflammation-induced The present invention describes methods of controlling and  
regulating the inflammatory 1998 expression of a reaction generated in response to  
various toxins, immunogens, pathogens and recombinant gene autoimmune insults. The  
method employs a vector that includes an anti-cytokine protein or antibacterial  
protein gene under the control of a cytokine responsive promoter. In animal models,  
adenoviral vectors successfully delivered the vectors to hepatic cells and were  
subsequently shown to respond only to stimulation by induced cytokines. 5,741,667  
Apr. 21, Tumor necrosis factor The invention concerns new tumor necrosis factor  
receptor associated factors, 1998 receptor-associated factors designated TRAFs. The  
new factors are capable of specific association with the intracellular domain of the  
type 2 TNF receptor (TNF-R2) and CD40, and are involved in the mediation of TNF and  
CD40 ligand biological activities. 5,741,488 Apr. 21, Treatment of rheumatoid A  
method for treating autoimmune or inflammatory diseases, through the administration  
of 1998 arthritis with anti-CD4 anti-CD4 antibody in conjunction with or sequentially

to anti-TNF antibody, is disclosed. antibodies in conjunction The method can be used to aid in therapy for humans and other mammals with a wide with anti-TNF antibodies variety of autoimmune or inflammatory diseases. 5,739,143 Apr. 14, Imidazole compounds and Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as 1998 compositions cytokine inhibitors. 5,736,570 Apr. 7, Immunotherapeutic aryl Novel aryl amides are inhibitors of tumor necrosis factor alpha and can be used to 1998 amides combat cachexia, endotoxic shock, and retrovirus replication A typical embodiment is N- benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)propanamide. 5,736,138 Apr. 7, Monoclonal antibodies with A monoclonal antibody, or fragments thereof, against human TNF receptor protein which 1998 specific binding against antibody neutralizes the known actions of TNF alpha and/or TNF beta is disclosed. The membrane proteins on antibody may be chimeric or humanized. Furthermore, the present invention provides a human cells, and process for obtaining the above monoclonal antibody, as well as a pharmaceutical pharmaceutical composition containing the above monoclonal antibody and/or the above protein with compositions containing antibody properties. them 5,731,343 Mar. 24, Method of use of radicicol The present invention provides a method of treating an immunopathological disorder 1998 for treatment of having an etiology associated with production of a proinflammatory agent, by administering immunopathological a compound of the formula: [See Original Patent for Chemical Structure Diagram] where disorders R1 and R2 are independently H or --COR3; R3 is H, 1-50C alkyl, 1-20C alkoxy, 2-30C alkenyl, 2-30C alkenyloxy, 2-10 alkynyl, 6-14C aryl or aryloxy, a 5-6 membered heterocycle (containing 1-3 N, O and/or S heteroatoms and optionally fused to an aryl group), 3-8C cycloalkyl (optionally fused to aryl) or 5-8C cycloalkenyl; and R4 is a halogen. Examples of such proinflammatory agents include interleukin-1 (IL-1), interleukin-6 (IL-6), interferon- gamma (IFN- gamma ), tumor necrosis factor- alpha (TNF- alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), the growth related gene KC, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), macrophage chemotactic protein (MCP), inducible nitric oxide synthetase (iNOS), macrophage inflammatory protein (MIP), tissue factor (TF), phosphotyrosine phosphatase (PTPase), and endotoxin. 5,730,975 Mar. 24, Treatment of insulin An induction of TNF- alpha mRNA expression has been observed in adipose tissue from 1998 resistance in obesity linked four different insulin resistant rodent models of obesity and diabetes. TNF- alpha protein type II diabetes using was also elevated locally and systemically. Neutralization of TNF- alpha in obese fa/fa rats antagonist to TNF-alpha caused a significant increase in the peripheral uptake of glucose in response to insulin. A function method of treating an animal suffering from insulin resistance in obesity linked Type II diabetes mellitus is disclosed. The method includes providing a therapeutic agent that includes an antagonist to TNF-alpha function in a pharmaceutically acceptable carrier substance and administering a pharmacologically effective amount of the therapeutic agent to the animal. 5,728,845 Mar. 17, Immunotherapeutic nitrites Novel nitrites are inhibitors of tumor necrosis factor alpha and phosphodiesterase and can 1998 be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3-Phthalimido-3-(3,4-